- Home
- AVXL vs BYRN Comparison
AVXL vs BYRN Comparison
Compare AVXL & BYRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVXL
- BYRN
- Stock Information
- Founded
- AVXL 2004
- BYRN 2005
- Country
- AVXL United States
- BYRN United States
- Employees
- AVXL N/A
- BYRN N/A
- Industry
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- BYRN Industrial Machinery/Components
- Sector
- AVXL Health Care
- BYRN Miscellaneous
- Exchange
- AVXL Nasdaq
- BYRN Nasdaq
- Market Cap
- AVXL 779.5M
- BYRN 626.0M
- IPO Year
- AVXL N/A
- BYRN N/A
- Fundamental
- Price
- AVXL $8.56
- BYRN $17.15
- Analyst Decision
- AVXL Strong Buy
- BYRN Strong Buy
- Analyst Count
- AVXL 2
- BYRN 3
- Target Price
- AVXL $44.00
- BYRN $22.08
- AVG Volume (30 Days)
- AVXL 1.1M
- BYRN 643.1K
- Earning Date
- AVXL 05-08-2025
- BYRN 04-10-2025
- Dividend Yield
- AVXL N/A
- BYRN N/A
- EPS Growth
- AVXL N/A
- BYRN N/A
- EPS
- AVXL N/A
- BYRN 0.55
- Revenue
- AVXL N/A
- BYRN $85,756,000.00
- Revenue This Year
- AVXL N/A
- BYRN $30.15
- Revenue Next Year
- AVXL N/A
- BYRN $22.53
- P/E Ratio
- AVXL N/A
- BYRN $31.18
- Revenue Growth
- AVXL N/A
- BYRN 101.10
- 52 Week Low
- AVXL $3.25
- BYRN $7.79
- 52 Week High
- AVXL $14.44
- BYRN $34.78
- Technical
- Relative Strength Index (RSI)
- AVXL 44.03
- BYRN 32.97
- Support Level
- AVXL $9.21
- BYRN $16.17
- Resistance Level
- AVXL $9.87
- BYRN $18.36
- Average True Range (ATR)
- AVXL 0.61
- BYRN 1.15
- MACD
- AVXL -0.13
- BYRN 0.09
- Stochastic Oscillator
- AVXL 33.06
- BYRN 18.39
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
About BYRN Byrna Technologies Inc.
Byrna Technologies Inc is a designer, manufacturer, retailer, and distributor of technological solutions for security situations that do not require the use of lethal force. The company generates its revenue from the United States, South Africa, Europe, South America, Asia, and Canada.